Lymphatic vessel contractile activity and intestinal inflammation

Memorias do Instituto Oswaldo Cruz

Volumn 100, Issue SUPPL. 1, 2005, Pages 107-110

  Wu, Theresa F ^a   MacNaughton, Wallace K ^a   Von Der Weid, Pierre Yves ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Crohn's disease; Edema; Inflammation; Lymphatic pumping; Lymphatic vessel; Prostanoids

Indexed keywords

7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; AUTACOID; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INDOMETACIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PROSTANOID;

CONFERENCE PAPER; DIET THERAPY; DIGESTIVE SYSTEM INFLAMMATION; EDEMA; ENTERITIS; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNITY; INFLAMMATION; LYMPH FLOW; LYMPH VESSEL; LYMPHATIC SYSTEM; MEDIATOR; NONHUMAN; PROPHYLAXIS; TISSUE WATER;

ANIMALIA;

EID: 18844411341     PISSN: 00740276     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0074-02762005000900018     Document Type: Conference Paper

References (23)

1. Allison MC, Dhillon AP, Lewis WG, Pounder RE 1998. Inflammatory Bowel Disease, Mosby International Limited, Barcelona, Spain.
2. Benoit JN, Zawieja DC, Goodman AH, Granger HJ 1989. Characterization of intact mesenteric lymphatic pump and its responsiveness to acute edemagenic stress. Am J Physiol 257: H2059-H2069.
3. Fogt F, Pascha TL, Zhang PJ, Gausas RE, Rahemtuly A, Zimmerman RL 2004. Proliferation of D2-40-espressing intestingal lymphatic vessels in the almina propria in inflammatory bowel disease. Int J Molec Med 13: 211-214.
4. 2. Br J Pharmacol 127: 1597-1602.
5. Geleff S, Schoppmann SF, Oberhuber G 2003. Increase in podoplanin-expressing intestinal lymphatic vessels in inflammatory bowel disease. Virchows Arch 442: 231-237.
6. Hawkey CJ, Rampton DS 1985. Prostaglandins and the gastrointestinal mucosa: are they important in its function, disease or treatment? Gastroenterology 89: 1162-1188.
7. Heatley RV, Bolton PM, Hughes LE, Owen EW 1980. Mesenteric lymphatic obstruction in Crohn's disease. Digestion 20: 307-313.
8. Johnston MG 1987. Interaction of inflammatory mediators with the lymphatic vessel. Pathol Immunopathol Res 6: 177-189.
9. Johnston MG, Gordon JL 1981. Regulation of lymphatic contractility by arachidonate metabolites. Nature 293: 294-297.
10. Kaiserling E, Krober S, Geleff S 2003. Lymphatic vessels in the colonic mucosa in ulcerative colitis. Lymphology 36: 52-61.
11. Kalima TV, Salomiemi H, Rahko T 1976. Experimental regional enteritis in pigs. Scand J Gastro 11: 353-362.
12. Kirsner JB, Shorter RG 1975. Inflammatory Bowel Disease, Lea and Febiger. Philadelphia.
13. 2 regulates macrophage derived tumor necrosis factor gene expression. J Biochem 263: 5380-5384.
14. Mizuno R, Koller A, Kaley G 1998. Regulation of the vasomotor activity of lymph micorvessels by nitric oxide and prostaglandins. Am J Physiol 274: R790-R796.
15. Mooney EE, Walker J, Hourihane DO 1995. Relation of granulomas to lymphatic vessels in Crohn's Disease. J Clin Pathol 48: 335-338.
16. 2. Br J Pharmacol 121: 1589-1596.
17. Reichert FL, Mathes ME 1936. Experimental lymphedema of the intestinal tract and its relation to regional cicatrizing enteritis. Ann Surg 104: 610-616.
18. Reuter MK, Asfaha S, Buret A, Sharkey KA, Wallace JL 1998. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxegenase-2. J Clin Invest 98: 2076-2085.
19. Robb-Smith AHT 1971. Symposium on Crohn's disease. Proc Royal Soc Med 64: 157-167.
20. Ryan TJ 1989. Structure and function of lymphatics. J Invest Dermatol 93: 18S-23S.
21. Santucci L, Fiorucci S, Giansanti M, Brunori PM, Dimatteo FN, Morelli A 1994. Petnoxifylline prevents indomethacin-induced acute mucosal damage in rats: role of tumour necrosis factor. Gut 35: 909-915.
22. Tonelli P 2000. New developments in Crohn's disease: solution of doctrinal mysteries and reinstatement as a surgically treatable disease. 1. The process is not a form of enteritis but lymphedema contaminated by intestinal contents. Chir Ital 52: 109-121.
23. Vane JR 1971. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231: 232-235.